AbbVie Inc. (ABBV)
AbbVie Stock Declines as Schizophrenia Studies Fail, BMY Gains
ABBV stock tumbles 13% after two mid-stage schizophrenia studies on emraclidine fail to meet their primary endpoint. BMY stock rises.
AbbVie's disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say
AbbVie's “pain” is Bristol Myers Squibb's “gain,” says Truist Securities analyst Srikripa Devarakonda.
Buy, Sell, Or Hold AbbVie Stock?
AbbVie stock (NYSE: ABBV) was down 12% on Monday, November 11, after the company announced that two mid-stage clinical trials of its drug Emraclidine to treat schizophrenia failed to meet their primary goal. [1] Emraclidine was developed by Cerevel Therapeutics, which AbbVie acquired for around $9 billion earlier this year.
AbbVie And Pfizer: Q3 Dividend Checkup Post-Earnings
I review both AbbVie and Pfizer's recent earnings reports via the window of dividends following Peter Lynch's wisdom. Lynch's insights into dividend stocks are often in the shadow of his reputation as a legendary growth investor. These insights, when overlooked, are an unfortunate loss for dividend investors.
Is AbbVie Still A Strong Buy After Fantastic Gains? (Rating Downgrade)
AbbVie investors that bought the anxiety over the loss of Humira exclusivity are sitting on massive gains. There are three significant reasons for optimism from here. However, the dividend yield is near its lowest point in six years; it may pay to wait for another dip.
AbbVie Stock: Keep Calm And Buy The Dip
AbbVie shares dropped nearly 10% after its schizophrenia drug emraclidine failed in late-stage trials. The market reaction appears excessive and presents a buying opportunity. Dividend yield and robust drug pipeline are bullish going forward.
Why AbbVie Stock Was Getting Mashed on Monday
A splashy recent acquisition by the company might not be panning out.
AbbVie stock drops 12% on schizophrenia drug setback: should you buy the dip?
AbbVie Inc (NYSE: ABBV) saw its stock fall nearly 13% after reporting disappointing mid-stage trial results for emraclidine, an experimental treatment for schizophrenia. This setback is notable as AbbVie had invested $8.
Trade Tracker: Jim Lebenthal buys more Abbvie
Jim Lebenthal, chief equity strategist at Cerity Partners, joins CNBC's 'Halftime Report' to discuss why he's buying more of the pharma stock on this dip.
AbbVie's Emraclidine For Schizophrenia 'Surprisingly Disappoints,' Analyst Says Pipeline Is Underappreciated
On Monday, AbbVie Inc ABBV stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia failed two Phase 2 trials.
AbbVie Stock Sinks After Schizophrenia Drug Trials Disappoint
Shares of AbbVie (ABBV) plummeted Monday after the company said its schizophrenia drug Emraclidine missed key goals in a pair of Phase 2 clinical trials.
AbbVie: Emraclidine's Failure Eliminates An Important Growth Driver
Emraclidine's failure in phase 2 trials is a significant setback for AbbVie's neuroscience pipeline. This was a very surprising outcome after very strong phase 1b results and the success of competitor Cobenfy in clinical trials in schizophrenia patients. Emraclidine was the main reason AbbVie acquired Cerevel for $8.7 billion, and I expect a substantial impairment charge on this deal.
